ATAI Life Sciences N.V. Common Shares (ATAI) Dividend History

Company News

• Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight

  The depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is expanding with the introduction of innovative antidepressants, psychedelic-based treatments, and digital therapeutics.

  GlobeNewswire Inc.

  Featured Companies: AXSM GHRS JNJ LPCN RLMD SAGE
• atai Life Sciences Announces Pricing of Public Offering of Common Shares

  atai Life Sciences, a clinical-stage biopharmaceutical company, announced the pricing of a registered underwritten offering of 26,190,477 common shares at $2.10 per share, raising approximately $55 million. The company intends to use the net proceeds for general corporate purposes, including advancing the clinical development of its product candidates.

  GlobeNewswire Inc.
• 5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

  The 5-HT2 agonist pipeline is robust, with over 20 pharmaceutical companies actively developing 22+ pipeline drugs. Advancements in precision medicine and personalized approaches are driving the market, enabling selective targeting of receptor subtypes and improving safety and efficacy.

  GlobeNewswire Inc.

  Featured Companies: CYBN HRMY MNMD RVPH
• 4 Psychedelic Stocks to Consider as Clinical Trials Heat up

  Several biotechnology firms have psychedelic treatments in development, with promising results from clinical trials. The psychedelic market is expected to grow significantly, and most investors are favorable towards psychedelic stocks.

  Investing.com

  Featured Companies: MNMD
• atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

  NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company’s participation:

  GlobeNewswire Inc.